Hematopoietic stem cell transplantation in mantle cell lymphoma
Open Access
- 1 April 2005
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 16 (4), 618-624
- https://doi.org/10.1093/annonc/mdi107
Abstract
Background: Patients with mantle cell lymphoma (MCL) have in general, lower response rates and overall survival (OS) than those with other B-cell non-Hodgkin's lymphomas. The role of hematopoietic stem cell transplantation (HSCT) in MCL is unclear. Hence we decided to study the clinical course of patients who received autologous and allogeneic HSCT for MCL. Methods: Ninety-seven patients, (80 patients-autologous; 17 patients-allogeneic) who received a HSCT for mantle cell lymphoma were included in the study. Results: The complete response rates at day 100 between the two groups were similar (73% vs. 62%). Day-100 mortality was higher in the allogeneic HSCT group (19% vs. 0%) (P < 0.01). The estimated 5-year relapse rates, 5-year event-free survival (EFS) and 5-year OS among the allogeneic HSCT patients were 21%, 44% and 49%, respectively, similar to 56%, 39% and 47% in the autologous group. Ten patients received HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone + high-dose methotrexate and cytarabine) ± rituximab prior to transplant. There have been no relapses or deaths amongst these patients at a median follow-up of 16 months. Conclusions: Patients treated with allogeneic HSCT had a lower relapse rate, but similar EFS and OS to autologous HSCT. Treatment of MCL with HyperCVAD ± rituximab followed by HSCT seems promising.Keywords
This publication has 28 references indexed in Scilit:
- Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remissionCancer, 2003
- Nonablative Allogeneic Stem-Cell Transplantation for Advanced/Recurrent Mantle-Cell LymphomaJournal of Clinical Oncology, 2003
- Syngeneic Hematopoietic Stem-Cell Transplantation for Non-Hodgkin’s Lymphoma: A Comparison With Allogeneic and Autologous Transplantation—The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow TransplantationJournal of Clinical Oncology, 2003
- Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective studyLeukemia, 2002
- Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free SurvivalJournal of Clinical Oncology, 2002
- Frontline transplantation of autologous CD34+ selected blood cells for advanced mantle cell lymphoma: no evidence of long-term cure: a single centre experienceBone Marrow Transplantation, 2000
- Mixed lymphohaemopoietic chimerism and graft-ver suslymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantationThe Lancet, 1999
- Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effectBone Marrow Transplantation, 1997
- Treatment of mantle-cell lymphomas with the VAD +/− chiorambucil regimen with or without subsequent high-dose therapy and peripheral blood stem-cell transplantationAnnals of Oncology, 1997
- Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosisHematological Oncology, 1989